Shionogi Limited, the London-based European subsidiary of Shionogi & Co., Ltd announce that the European Medicines Agency (EMA) accepted its Marketing Authorisation Application (MAA) submission for naldemedine.. read more..
Shionogi Inc. and Purdue Pharma L.P. announce that the U.S. Food and Drug Administration (FDA) approved Symproic® (naldemedine) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. read more ..
Shionogi & Co., Ltd. (hereafter “Shionogi”) announced that Symproic® (generic name: naldemedine tosilate) was approved today by the Ministry of Health, Labor and Welfare for the treatment of opioid-induced constipation (OIC). Read more .
If you are interested in joining Shionogi, visit the join us page!